...
首页> 外文期刊>Advances in Interventional Cardiology: Postepy w Kardiologii Interwencyjnej >Conservative strategy in patients with non-ST-segment elevation acute coronary syndromes
【24h】

Conservative strategy in patients with non-ST-segment elevation acute coronary syndromes

机译:非ST段抬高急性冠脉综合征的保守策略

获取原文

摘要

Background : Clinical outcomes of patients with non-ST-segment elevation acute coronary syndrome (NSTACS) disqualified from an invasive strategy (InvS) remain incompletely understood. Aim : To investigate short-term results of a conservative strategy (ConS) in a real-life population of patients with NSTACS. Material and methods : 526 patients with NSTACS were retrospectively analysed. Of these, 335 (63.7%) patients were initially qualified for the ConS. In the remaining 191 (36.3%) patients an InvS was applied. Results : The most frequent reasons for disqualification from an InvS in NSTACS patients were TIMI risk score ? 4 (88.0%), lack of patient consent (3.9%) and pulmonary oedema (3.0%). In the group of InvS, cardiogenic shock on admission was found in 11 (5.8%) patients. In patients who underwent ConS and InvS 30-day mortality rate was 6.0 and 10.5% (p = 0.061), respectively, whereas 30-day mortality in non-shock patients assigned to InvS was 7.9% (p = 0.40 vs. ConS). During primary hospitalization, 27 (8.1%) patients with ConS and 7 (3.7%) with InvS developed symptoms of heart failure (Killip 2-4) (p = 0.049). In the group of InvS, cardiogenic shock on admission (OR 49.5, 95% CI 125-234.2, p Conclusions : In NSTACS patients, low risk of complications at baseline was the main reason for disqualification from InvS. The mortality rate within 30 days did not differ significantly between the two therapeutic groups. Symptoms of heart failure during hospitalization were an independent predictor of death within 30 days in NSTACS patients disqualified from InvS.
机译:背景:非侵入性策略(InvS)被取消资格的非ST段抬高的急性冠状动脉综合征(NSTACS)患者的临床结局仍未完全了解。目的:研究保守策略(ConS)在NSTACS患者真实人群中的短期结果。材料与方法:回顾性分析526例NSTACS患者。其中,有335名(63.7%)患者最初符合ConS的资格。在其余191名(36.3%)患者中,应用了InvS。结果:NSTACS患者因InvS失格的最常见原因是TIMI风险评分? 4(88.0%),未征得患者同意(3.9%)和肺水肿(3.0%)。在InvS组中,有11名(5.8%)患者入院时发现了心源性休克。接受ConS和InvS治疗的患者,其30天死亡率分别为6.0和10.5%(p = 0.061),而分配给InvS的非休克患者的30天死亡率为7.9%(相对于ConS,p = 0.40)。在初次住院期间,有27名(8.1%)的ConS患者和7名(3.7%)的InvS患者出现心力衰竭症状(Killip 2-4)(p = 0.049)。在InvS组,入院时发生心源性休克(OR 49.5,95%CI 125-234.2,p)结论:在NSTACS患者中,基线并发症风险低是InvS不合格的主要原因。30天内的死亡率两组住院期间心力衰竭的症状是30天内因InvS失格的NSTACS患者死亡的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号